Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 382582, 8 pages
http://dx.doi.org/10.1155/2010/382582
Clinical Study

Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus

1Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
2Center for Experimental and Molecular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
3Department of Pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Received 22 December 2009; Accepted 21 March 2010

Academic Editor: Paul Magnus Schneider

Copyright © 2010 Agnieszka M. Rygiel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. J. Shaheen, “Advances in Barrett's esophagus and esophageal adenocarcinoma,” Gastroenterology, vol. 128, no. 6, pp. 1554–1566, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. B. O'Connor, G. W. Falk, and J. E. Richter, “The incidence of adenocarcinoma and dysplasia in Barrett's esophagus report on the Cleveland Clinic Barrett's Esophagus Registry,” American Journal of Gastroenterology, vol. 94, no. 8, pp. 2037–2042, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. S. S. Devesa, W. J. Blot, and J. F. Fraumeni Jr., “Changing patterns in the incidence of esophageal and gastric carcinoma in the United States,” Cancer, vol. 83, no. 10, pp. 2049–2053, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Peracchia, L. Bonavina, A. Via, and R. Incarbone, “Current trends in the surgical treatment of esophageal and cardia adenocarcinoma,” Journal of Experimental and Clinical Cancer Research, vol. 18, no. 3, pp. 289–294, 1999. View at Google Scholar · View at Scopus
  5. B. J. Reid, R. C. Haggitt, C. E. Rubin et al., “Observer variation in the diagnosis of dysplasia in Barrett's esophagus,” Human Pathology, vol. 19, no. 2, pp. 166–178, 1988. View at Google Scholar · View at Scopus
  6. E. Montgomery, M. P. Bronner, J. R. Goldblum et al., “Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation,” Human Pathology, vol. 32, no. 4, pp. 368–378, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Mueller, M. Werner, and M. Stolte, “Barrett's esophagus: histopathologic definitions and diagnostic criteria,” World Journal of Surgery, vol. 28, no. 2, pp. 148–154, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. A. R. Bianco, “Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications,” Journal of Chemotherapy, vol. 16, no. 4, pp. 52–54, 2004. View at Google Scholar · View at Scopus
  9. S. Ménard, E. Tagliabue, M. Campiglio, and S. M. Pupa, “Role of HER2 gene overexpression in breast carcinoma,” Journal of Cellular Physiology, vol. 182, no. 2, pp. 150–162, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. J. S. Ross and J. A. Fletcher, “The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy,” Stem Cells, vol. 16, no. 6, pp. 413–428, 1998. View at Google Scholar · View at Scopus
  11. E. Tzahar and Y. Yarden, “The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands,” Biochimica et Biophysica Acta, vol. 1377, no. 1, pp. M25–M37, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1673–1684, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Al-Kasspooles, J. H. Moore, M. B. Orringer, and D. G. Beer, “Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas,” International Journal of Cancer, vol. 54, no. 2, pp. 213–219, 1993. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Jankowski, G. Coghill, D. Hopwood, and K. G. Wormsley, “Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus,” Gut, vol. 33, no. 8, pp. 1033–1038, 1992. View at Google Scholar · View at Scopus
  16. J.-F. Flejou, F. Paraf, F. Muzeau et al., “Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations,” Journal of Clinical Pathology, vol. 47, no. 1, pp. 23–26, 1994. View at Google Scholar · View at Scopus
  17. R. Kim, M. R. Clarke, M. F. Melhem et al., “Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma,” Digestive Diseases and Sciences, vol. 42, no. 12, pp. 2453–2462, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Geddert, M. Zeriouh, M. Wolter, J. W. Heise, H. E. Gabbert, and M. Sarbia, “Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions,” American Journal of Clinical Pathology, vol. 118, no. 1, pp. 60–66, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Walch, K. Specht, K. Bink et al., “Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus,” Laboratory Investigation, vol. 81, no. 6, pp. 791–801, 2001. View at Google Scholar · View at Scopus
  20. E. Rossi, V. Villanacci, G. Bassotti et al., “Her-2/neu in Barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization,” Diagnostic Molecular Pathology, vol. 15, no. 3, pp. 125–130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Safran, T. DiPetrillo, P. Akerman et al., “Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 67, no. 2, pp. 405–409, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Penault-Llorca, J. Adelaide, G. Houvenaeghel, J. Hassoun, D. Birnbaum, and J. Jacquemier, “Optimization of immunohistochemical detection of ERBB 2 in human breast cancer: impact of fixation,” Journal of Pathology, vol. 173, no. 1, pp. 65–75, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. M. F. Press, G. Hung, W. Godolphin, and D. J. Slamon, “Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression,” Cancer Research, vol. 54, no. 10, pp. 2771–2777, 1994. View at Google Scholar · View at Scopus
  24. D. L. Persons, M. M. Bui, M. C. Lowery et al., “Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study,” Annals of Clinical and Laboratory Science, vol. 30, no. 1, pp. 41–48, 2000. View at Google Scholar · View at Scopus
  25. T. P. Brien, R. D. Odze, C. E. Sheehan, B. J. McKenna, and J. S. Ross, “Her-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma,” Human Pathology, vol. 31, no. 1, pp. 35–39, 2000. View at Google Scholar · View at Scopus
  26. S. M. Brankley, K. K. Wang, A. R. Harwood et al., “The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus,” Journal of Molecular Diagnostics, vol. 8, no. 2, pp. 260–267, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. A. M. Rygiel, J. W. van Baal, F. Milano et al., “Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population,” Cancer, vol. 109, no. 10, pp. 1980–1988, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Tbakhi, G. Totos, C. Hauser-Kronberger et al., “Fixation conditions for DNA and RNA in situ hybridization: a reassessment of molecular morphology dogma,” American Journal of Pathology, vol. 152, no. 1, pp. 35–41, 1998. View at Google Scholar · View at Scopus
  29. B. J. Reid, P. L. Blount, Z. Feng, and D. S. Levine, “Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia,” American Journal of Gastroenterology, vol. 95, no. 11, pp. 3089–3096, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. F. P. Peters, K. K. Krishnadath, A. M. Rygiel et al., “Stepwise radical endoscopic resection of the complete Barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities,” American Journal of Gastroenterology, vol. 102, no. 9, pp. 1853–1861, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Walch, K. Bink, P. Gais et al., “Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma,” Analytical Cellular Pathology, vol. 20, no. 1, pp. 25–32, 2000. View at Google Scholar · View at Scopus
  32. J. Couturier, A. Vincent-Salomon, A. Nicolas et al., “Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma,” Modern Pathology, vol. 13, no. 11, pp. 1238–1243, 2000. View at Google Scholar · View at Scopus
  33. M. Dowsett, J. Bartlett, I. O. Ellis et al., “Correlation between immunohistochemistry (Hercep Test) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres,” Journal of Pathology, vol. 199, no. 4, pp. 418–423, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Mayr, V. Kanitz, G. Amann et al., “HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays,” Histopathology, vol. 48, no. 2, pp. 149–156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. C. C. Maley, P. C. Galipeau, J. C. Finley et al., “Genetic clonal diversity predicts progression to esophageal adenocarcinoma,” Nature Genetics, vol. 38, no. 4, pp. 468–473, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. D. L. Persons, K. A. Borelli, and P. H. Hsu, “Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization,” Modern Pathology, vol. 10, no. 7, pp. 720–727, 1997. View at Google Scholar · View at Scopus
  37. O.-P. Kallioniemi, A. Kallioniemi, W. Kurisu et al., “ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5321–5325, 1992. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Pauletti, W. Godolphin, M. F. Press, and D. J. Slamon, “Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization,” Oncogene, vol. 13, no. 1, pp. 63–72, 1996. View at Google Scholar · View at Scopus
  39. L. Hammock, M. Lewis, C. Phillips, and C. Cohen, “Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization,” Human Pathology, vol. 34, no. 10, pp. 1043–1047, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Hofmann, O. Stoss, T. Gaiser et al., “Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy,” Journal of Clinical Pathology, vol. 61, no. 1, pp. 89–94, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Safran, T. DiPetrillo, A. Nadeem et al., “Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study,” Cancer Investigation, vol. 22, no. 5, pp. 670–677, 2004. View at Publisher · View at Google Scholar · View at Scopus